

Solexa, Inc.
Form 3
March 14, 2005

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â OXFORD BIOSCIENCE PARTNERS IV LP			(Month/Day/Year)	Solexa, Inc. [SLXA]	
(Last)	(First)	(Middle)		4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
222 BERKELEY ST.				(Check all applicable)	6. Individual or Joint/Group Filing(Check Applicable Line)
(Street)				___ Director	___ Form filed by One Reporting Person
BOSTON,Â MAÂ 02116				___ Officer	___ Form filed by More than One Reporting Person
(City)	(State)	(Zip)		(give title below)	(specify below)

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common	2,468,986	D ⁽¹⁾	Â
Common	24,771	I	By mRNA Fund II L.P. ⁽²⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
--	--	---	------------------------------------	---------------------------------	---

Edgar Filing: Solexa, Inc. - Form 3

Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)
---------------------	--------------------	-------	----------------------------------	------------------------	---

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
OXFORD BIOSCIENCE PARTNERS IV LP 222 BERKELEY ST. BOSTON, MA 02116	^	^ X	^	^
MRNA FUND II LP 222 BERKELEY ST. BOSTON, MA 02116	^	^ X	^	^
OBP MANAGEMENT IV LP 222 BERKELEY ST. BOSTON, MA 02116	^	^ X	^	^
BARNES JEFFREY T 222 BERKELEY ST. BOSTON, MA 02116	^	^ X	^	^
CARTHY MARK 222 BERKELEY ST. BOSTON, MA 02116	^ X	^ X	^	^
FLEMING JONATHAN 222 BERKELEY ST. BOSTON, MA 02116	^	^ X	^	^
LYTTON MICHAEL 222 BERKELEY ST. BOSTON, MA 02116	^	^ X	^	^
WALTON ALAN G 222 BERKELEY ST. BOSTON, MA 02116	^	^ X	^	^

Signatures

/s/ Jonathan J. Fleming, as general partner of the general partner of Oxford Bioscience Partners IV L.P.	03/14/2005
**Signature of Reporting Person	Date
/s/ Jonathan J. Fleming, as general partner of the general partner of mRNA Fund II L.P.	03/14/2005
**Signature of Reporting Person	Date
/s/ Jonathan J. Fleming, as general partner of OBP Management IV L.P.	03/14/2005
**Signature of Reporting Person	Date
/s/ Raymond Charest, as attorney-in-fact for Jeffrey T. Barnes	03/14/2005

Edgar Filing: Solexa, Inc. - Form 3

	<u> </u> **Signature of Reporting Person	Date
/s/ Mark P. Carthy		03/14/2005
	<u> </u> **Signature of Reporting Person	Date
/s/ Jonathan J. Fleming		03/14/2005
	<u> </u> **Signature of Reporting Person	Date
/s/ Michael E. Lytton		03/14/2005
	<u> </u> **Signature of Reporting Person	Date
/s/ Alan G. Walton		03/14/2005
	<u> </u> **Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Securities held of record by Oxford Bioscience Partners IV L.P. ("Oxford IV"). By virtue of their relationship as affiliated limited partnerships, whose sole general partner shares individual general partners, Oxford IV and mRNA Fund II L.P. ("mRNA") may be deemed to share voting power and the power to direct the disposition of the shares which each partnership owns of record. OBP

(1) Management IV L.P. ("OBP IV") (as the general partner of Oxford IV and mRNA II), may also be deemed to own beneficially the shares held of record by Oxford IV and mRNA II. Each of Messrs. Barnes, Carthy (who is a Director of the issuer), Fleming, Lytton, and Walton, the individual general partners of OBP IV, may be deemed to own beneficially the shares held by Oxford IV and mRNA II.

Securities held of record by mRNA. By virtue of their relationship as affiliated limited partnerships, whose sole general partner shares individual general partners, Oxford IV and mRNA may be deemed to share voting power and the power to direct the disposition of the shares which each partnership owns of record. OBP IV (as the general partner of Oxford IV and mRNA II), may also be deemed to own beneficially the shares held of record by Oxford IV and mRNA II. Each of Messrs. Barnes, Carthy (who is a Director of the issuer), Fleming, Lytton, and Walton, the individual general partners of OBP IV, may be deemed to own beneficially the shares held by Oxford IV and mRNA II.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.